Pharma BD Deal Intelligence
J&J bought its way into insulin pumps in 2006 and completely exited the business in 2017 — an 11-year, ~$518M dead end
Full analysis, sources & comparables →Animas 8-K disclosing the definitive merger agreement with Johnson & Johnson, $24.50 per share in cash, with the transaction expected to close in the first…
Coverage frames the deal as J&J's LifeScan entering the fast-growing insulin delivery pump market, a strategic complement to its blood-glucose monitoring…
J&J shuts down Animas insulin pump operations in US and Canada, transferring patients to Medtronic — a retrospective indictment of the original…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
J&J announces $518M acquisition of insulin pump maker Animas. Diabetes device deal. Closed Feb 17, 2006.
J&J bought its way into insulin pumps in 2006 and completely exited the business in 2017 — an 11-year, ~$518M dead end
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Johnson & Johnson / Animas Corporation (this deal) | 2005 | $518M | 23 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $9.0B | 96 |
| Johnson & Johnson / Centocor Inc. | 1999 | $4.9B | 92 |
| Johnson & Johnson / Cougar Biotechnology, Inc. | 2009 | $970M | 91 |
| Johnson & Johnson / Actelion Ltd | 2017 | $30.0B | 90 |
| Johnson & Johnson / Aragon Pharmaceuticals Inc. | 2013 | $1.0B | 89 |
| Johnson & Johnson / Legend Biotech Corporation | 2017 | $350M | 83 |
← Browse all deals · How we score deals
More: 2005 deals · Johnson & Johnson deals